Pfizer to acquire Global Blood Therapeutics for $5.4 billion, gaining sickle cell portfolio, pipeline
MLex Summary: Pfizer has agreed to acquire Global Blood Therapeutics for an enterprise value of $5.4 billion. The merger will give Pfizer a sickle cell disease portfolio, pipeline and expertise. The...To view the full article, register now.
Already a subscriber? Click here to view full article